About Keryx Biopharmaceuticals (NASDAQ:KERX)
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:KERX
CUSIP49251510
Phone617-466-3500
Debt
Debt-to-Equity Ratio-8.87%
Current Ratio3.12%
Quick Ratio2.49%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$60.64 million
Price / Sales8.94
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-37.92
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-163,440,000.00
Net Margins-269.52%
Return on Equity-10,954.62%
Return on Assets-62.33%
Miscellaneous
Employees210
Outstanding Shares119,180,000
Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions
What is Keryx Biopharmaceuticals' stock symbol?
Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."
How were Keryx Biopharmaceuticals' earnings last quarter?
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) issued its quarterly earnings results on Wednesday, February, 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.08. The biopharmaceutical company had revenue of $18.70 million for the quarter, compared to analysts' expectations of $17.53 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 269.52%. Keryx Biopharmaceuticals's revenue was up 96.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.32) EPS. View Keryx Biopharmaceuticals' Earnings History.
When is Keryx Biopharmaceuticals' next earnings date?
What price target have analysts set for KERX?
4 brokerages have issued 12-month target prices for Keryx Biopharmaceuticals' stock. Their predictions range from $5.00 to $9.00. On average, they anticipate Keryx Biopharmaceuticals' stock price to reach $6.6667 in the next twelve months. View Analyst Ratings for Keryx Biopharmaceuticals.
What are Wall Street analysts saying about Keryx Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Auryxia posted a good performance in 2017. The FDA approval for the label expansion of Auryxia to treat adults with iron deficiency anemia (IDA) and chronic kidney disease, not on dialysis, might boost sales of the company, given that the IDA market holds great potential. However, with Auryxia being the only approved product in Keryx’s portfolio, the company is completely dependent on it for growth. Meanwhile, Auryxia faces stiff competition in the United States from existing players, apart from over-the-counter drugs like some calcium carbonate and metal-based products. Also, Keryx may face strong pricing pressure for Auryxia. The company did not provide any guidance for 2018 as the company waits to see how Auryxia is adopted by the patients in the IDA setting. Consequently, shares of the company underperformed the industry." (4/11/2018)
- 2. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)
Who are some of Keryx Biopharmaceuticals' key competitors?
Some companies that are related to Keryx Biopharmaceuticals include Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Cambrex (CBM) and Insmed (INSM).
Who are Keryx Biopharmaceuticals' key executives?
Keryx Biopharmaceuticals' management team includes the folowing people:
- Mr. Gregory P. Madison, CEO, Pres & Director (Age 50)
- Mr. Scott A. Holmes, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 44)
- Mr. Brian R. Adams, Sr. VP, Gen. Counsel & Sec. (Age 44)
- Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)
- Ms. Christine A. Carberry, Sr. VP & COO (Age 57)
Has Keryx Biopharmaceuticals been receiving favorable news coverage?
News articles about KERX stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Keryx Biopharmaceuticals earned a coverage optimism score of 0.24 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Keryx Biopharmaceuticals?
Shares of KERX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Keryx Biopharmaceuticals' stock price today?
One share of KERX stock can currently be purchased for approximately $4.55.
How big of a company is Keryx Biopharmaceuticals?
Keryx Biopharmaceuticals has a market capitalization of $567.28 million and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Keryx Biopharmaceuticals employs 210 workers across the globe.
How can I contact Keryx Biopharmaceuticals?
Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected]
MarketBeat Community Rating for Keryx Biopharmaceuticals (KERX)
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KERX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KERX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Keryx Biopharmaceuticals (NASDAQ:KERX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Keryx Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 46.52%. The high price target for KERX is $9.00 and the low price target for KERX is $5.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.25 | 2.25 | 2.25 | 2.20 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.6667 | $6.6667 | $7.00 | $7.50 |
| Price Target Upside: | 46.52% upside | 56.49% upside | 42.56% upside | 0.94% upside |
Keryx Biopharmaceuticals (NASDAQ:KERX) Consensus Price Target History
Keryx Biopharmaceuticals (NASDAQ:KERX) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Keryx Biopharmaceuticals (NASDAQ:KERX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Keryx Biopharmaceuticals (NASDAQ KERX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.58%
Institutional Ownership Percentage: 65.50%
Keryx Biopharmaceuticals (NASDAQ KERX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/18/2018 | Christine A. Carberry | COO | Sell | 2,026 | $4.83 | $9,785.58 | |  |
| 2/15/2018 | Brian Adams | General Counsel | Sell | 5,652 | $4.81 | $27,186.12 | | |
| 2/15/2018 | Greg Madison | Insider | Sell | 15,318 | $4.81 | $73,679.58 | | |
| 2/15/2018 | Scott A Holmes | CFO | Sell | 5,651 | $4.81 | $27,181.31 | | |
| 1/29/2018 | Brian Adams | General Counsel | Sell | 1,541 | $4.81 | $7,412.21 | | |
| 1/29/2018 | Scott A. Holmes | CFO | Sell | 2,830 | $4.81 | $13,612.30 | | |
| 1/23/2018 | John F. Neylan | Insider | Sell | 1,322 | $4.92 | $6,504.24 | | |
| 1/18/2018 | Christine A. Carberry | COO | Sell | 9,048 | $4.87 | $44,063.76 | | |
| 1/5/2018 | Brian Adams | General Counsel | Sell | 753 | $4.69 | $3,531.57 | | |
| 1/5/2018 | Greg Madison | CEO | Sell | 1,067 | $4.69 | $5,004.23 | | |
| 10/30/2017 | Brian Adams | General Counsel | Sell | 1,405 | $6.03 | $8,472.15 | | |
| 10/30/2017 | Greg Madison | Insider | Sell | 4,055 | $6.03 | $24,451.65 | | |
| 10/30/2017 | Scott A. Holmes | CFO | Sell | 2,582 | $6.03 | $15,569.46 | | |
| 10/23/2017 | John F. Neylan | Insider | Sell | 1,179 | $6.53 | $7,698.87 | | |
| 10/5/2017 | Brian Adams | General Counsel | Sell | 630 | $7.19 | $4,529.70 | | |
| 10/5/2017 | Greg Madison | Insider | Sell | 895 | $7.19 | $6,435.05 | | |
| 7/31/2017 | John F. Neylan | Insider | Sell | 1,445 | $7.14 | $10,317.30 | | |
| 7/28/2017 | Scott A. Holmes | CFO | Sell | 1,236 | $6.96 | $8,602.56 | | |
| 7/24/2017 | John F. Neylan | Insider | Sell | 1,214 | $7.27 | $8,825.78 | | |
| 7/5/2017 | Brian Adams | General Counsel | Sell | 641 | $7.67 | $4,916.47 | | |
| 7/5/2017 | Greg Madison | Insider | Sell | 910 | $7.67 | $6,979.70 | | |
| 4/28/2017 | Scott A. Holmes | CFO | Sell | 1,219 | $5.89 | $7,179.91 | | |
| 4/24/2017 | John F. Neylan | Insider | Sell | 1,209 | $5.73 | $6,927.57 | | |
| 4/17/2017 | Brian Adams | General Counsel | Sell | 1,090 | $5.75 | $6,267.50 | | |
| 4/5/2017 | Brian Adams | General Counsel | Sell | 642 | $5.80 | $3,723.60 | | |
| 4/5/2017 | Greg Madison | Insider | Sell | 911 | $5.80 | $5,283.80 | | |
| 1/30/2017 | Brian Adams | General Counsel | Sell | 6,984 | $4.65 | $32,475.60 | | |
| 1/30/2017 | Greg Madison | Insider | Sell | 18,248 | $4.65 | $84,853.20 | | |
| 1/30/2017 | Scott A. Holmes | CFO | Sell | 8,447 | $4.65 | $39,278.55 | | |
| 1/23/2017 | John F. Neylan | Insider | Sell | 1,428 | $5.39 | $7,696.92 | | |
| 1/17/2017 | Brian Adams | VP | Sell | 1,265 | $6.24 | $7,893.60 | | |
| 1/5/2017 | Brian Adams | VP | Sell | 759 | $6.16 | $4,675.44 | | |
| 1/5/2017 | Greg Madison | Insider | Sell | 1,077 | $6.16 | $6,634.32 | | |
| 10/28/2016 | Scott A. Holmes | CFO | Sell | 1,237 | $4.44 | $5,492.28 | | |
| 10/24/2016 | John F. Neylan | Insider | Sell | 1,211 | $4.72 | $5,715.92 | | |
| 10/17/2016 | Brian Adams | VP | Sell | 1,106 | $4.86 | $5,375.16 | | |
| 10/5/2016 | Brian Adams | VP | Sell | 647 | $5.38 | $3,480.86 | | |
| 10/5/2016 | Greg Madison | Insider | Sell | 917 | $5.38 | $4,933.46 | | |
| 8/9/2016 | Greg Madison | Insider | Sell | 1,622 | $4.22 | $6,844.84 | | |
| 7/29/2016 | Scott A. Holmes | CFO | Sell | 4,935 | $7.36 | $36,321.60 | | |
| 7/25/2016 | John F. Neylan | Insider | Sell | 1,217 | $7.43 | $9,042.31 | | |
| 7/15/2016 | Brian Adams | VP | Sell | 1,083 | $7.01 | $7,591.83 | | |
| 7/5/2016 | Brian Adams | VP | Sell | 660 | $6.66 | $4,395.60 | | |
| 7/5/2016 | Greg Madison | CEO | Sell | 936 | $6.66 | $6,233.76 | | |
| 5/9/2016 | Greg Madison | CEO | Sell | 1,873 | $5.42 | $10,151.66 | 259,681 | |
| 4/25/2016 | John F Neylan | Insider | Sell | 4,766 | $5.21 | $24,830.86 | 93,984 | |
| 4/15/2016 | Brian Adams | VP | Sell | 1,060 | $5.05 | $5,353.00 | 105,063 | |
| 4/5/2016 | Brian Adams | VP | Sell | 759 | $4.50 | $3,415.50 | 106,123 | |
| 4/5/2016 | Greg Madison | CEO | Sell | 1,078 | $4.50 | $4,851.00 | 261,554 | |
| 2/9/2016 | Greg Madison | CEO | Sell | 1,938 | $3.23 | $6,259.74 | | |
| 1/15/2016 | Brian Adams | VP | Sell | 1,322 | $3.30 | $4,362.60 | 53,132 | |
| 1/6/2016 | Brian Adams | VP | Sell | 3,004 | $5.16 | $15,500.64 | 54,454 | |
| 1/6/2016 | Greg Madison | CEO | Sell | 4,261 | $4.83 | $20,580.63 | 110,820 | |
| 11/4/2015 | Scott A. Holmes | CFO | Buy | 5,000 | $5.33 | $26,650.00 | 59,742 | |
| 10/15/2015 | Brian Adams | VP | Sell | 1,011 | $4.01 | $4,054.11 | 57,458 | |
| 8/21/2015 | Scott A Holmes | CFO | Buy | 5,000 | $5.72 | $28,600.00 | 54,742 | |
| 7/15/2015 | Brian Adams | VP | Sell | 1,086 | $9.99 | $10,849.14 | | |
| 7/6/2015 | James F Oliviero III | CFO | Sell | 1,943 | $9.61 | $18,672.23 | | |
| 5/6/2015 | Michael P Tarnok | Director | Buy | 10,000 | $9.73 | $97,300.00 | | |
| 4/15/2015 | Brian Adams | VP | Sell | 4,320 | $12.40 | $53,568.00 | | |
| 4/6/2015 | James F Oliviero III | CFO | Sell | 1,878 | $11.68 | $21,935.04 | | |
| 4/6/2015 | Ron Bentsur | CEO | Sell | 1,592 | $11.68 | $18,594.56 | | |
| 3/6/2015 | Greg Madison | COO | Buy | 6,380 | $12.53 | $79,941.40 | | |
| 2/9/2015 | Greg Madison | COO | Sell | 6,759 | $10.95 | $74,011.05 | | |
| 1/5/2015 | James F Oliviero III | CFO | Sell | 5,604 | $13.79 | $77,279.16 | | |
| 1/5/2015 | Ron Bentsur | CEO | Sell | 5,574 | $13.79 | $76,865.46 | | |
| 12/30/2014 | Ron Bentsur | CEO | Sell | 200,000 | $14.11 | $2,822,000.00 | | |
| 12/29/2014 | Ron Bentsur | CEO | Sell | 338,977 | $13.98 | $4,738,898.46 | | |
| 10/6/2014 | Ron Bentsur | CEO | Sell | 70,838 | $15.88 | $1,124,907.44 | | |
| 10/3/2014 | James F Oliviero III | CFO | Sell | 2,694 | $16.14 | $43,481.16 | | |
| 9/12/2014 | Ron Bentsur | CEO | Sell | 50,000 | $14.24 | $712,000.00 | | |
| 9/8/2014 | James F Oliviero III | CFO | Sell | 144,237 | $15.88 | $2,290,483.56 | | |
| 7/7/2014 | James F Oliviero III | CFO | Sell | 2,054 | $15.75 | $32,350.50 | | |
| 7/7/2014 | Ron Bentsur | CEO | Sell | 1,788 | $15.75 | $28,161.00 | | |
| 4/3/2014 | James Oliviero III | CFO | Sell | 2,087 | $16.46 | $34,352.02 | 302,330 | |
| 4/3/2014 | Ron Bentsur | CEO | Sell | 1,816 | $16.46 | $29,891.36 | 878,603 | |
| 3/21/2014 | James Oliviero III | CFO | Sell | 292,483 | $15.14 | $4,428,192.62 | 304,417 | |
| 1/3/2014 | James Oliviero III | CFO | Sell | 6,309 | $12.57 | $79,304.13 | 492,861 | |
| 1/3/2014 | Ron Bentsur | CEO | Sell | 5,257 | $12.57 | $66,080.49 | 880,419 | |
| 12/30/2013 | James Oliviero III | CFO | Sell | 109,500 | $12.64 | $1,384,080.00 | 476,429 | |
| 10/3/2013 | James Oliviero III | CFO | Sell | 1,475 | $10.25 | $15,118.75 | 555,929 | |
| 10/3/2013 | Ron Bentsur | CEO | Sell | 2,505 | $10.25 | $25,676.25 | 459,065 | |
| 7/5/2013 | James F Oliviero III | CFO | Sell | 1,438 | $7.95 | $11,432.10 | | |
| 7/5/2013 | Ron Bentsur | CEO | Sell | 2,440 | $7.95 | $19,398.00 | | |
| 5/13/2013 | James F Oliviero III | CFO | Sell | 29,363 | $8.34 | $244,887.42 | | |
| 10/3/2012 | James F Oliviero III | CFO | Sell | 4,973 | $2.72 | $13,526.56 | | |
(Data available from 1/1/2013 forward)
Keryx Biopharmaceuticals (NASDAQ KERX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | $21.12 Million in Sales Expected for Keryx Biopharmaceuticals, Inc. (KERX) This Quarter
www.americanbankingnews.com - April 22 at 3:44 AM |
| Keryx Biopharmaceuticals (KERX) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 20 at 11:39 AM |
| Zacks: Analysts Anticipate Keryx Biopharmaceuticals, Inc. (KERX) to Post -$0.19 Earnings Per Share
www.americanbankingnews.com - April 20 at 11:35 AM |
 | Keryx Biopharma (KERX) Says Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress
www.streetinsider.com - April 19 at 4:58 PM |
 | Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress
finance.yahoo.com - April 19 at 9:22 AM |
| Keryx Biopharmaceuticals (KERX) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:16 PM |
| Keryx Biopharmaceuticals (KERX) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - April 17 at 1:54 PM |
| BidaskClub Downgrades Keryx Biopharmaceuticals (KERX) to Hold
www.americanbankingnews.com - April 16 at 9:16 AM |
| Keryx Biopharmaceuticals (KERX) Given a $9.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 15 at 4:33 PM |
| Keryx Biopharmaceuticals (KERX) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - April 14 at 1:59 PM |
| Keryx Biopharmaceuticals (KERX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 7:41 PM |
| Keryx Biopharmaceuticals (KERX) Downgraded by BidaskClub
www.americanbankingnews.com - April 12 at 6:15 PM |
| Today’s Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay Therapeutics
finance.yahoo.com - April 12 at 9:52 AM |
| Keryx Biopharmaceuticals (KERX) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM |
| Zacks Investment Research Upgrades Keryx Biopharmaceuticals (KERX) to "Hold"
www.americanbankingnews.com - April 11 at 9:52 AM |
| Keryx Biopharmaceuticals (KERX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:13 AM |
| Keryx Biopharmaceuticals (KERX) Expected to Post Quarterly Sales of $21.12 Million
www.americanbankingnews.com - April 5 at 3:58 AM |
| Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology
finance.yahoo.com - April 4 at 9:14 AM |
| Keryx Biopharmaceuticals (KERX) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 3 at 11:14 AM |
| Stifel Nicolaus Lowers Keryx Biopharmaceuticals (KERX) Price Target to $5.00
www.americanbankingnews.com - April 1 at 9:46 AM |
| Keryx Biopharmaceuticals (KERX) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - March 24 at 12:28 PM |
| Keryx Biopharmaceuticals (KERX) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - March 24 at 10:48 AM |
| Brokerages Anticipate Keryx Biopharmaceuticals (KERX) Will Announce Quarterly Sales of $21.12 Million
www.americanbankingnews.com - March 19 at 5:52 AM |
| Keryx Biopharmaceuticals (KERX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 18 at 7:42 PM |
| -$0.19 Earnings Per Share Expected for Keryx Biopharmaceuticals (KERX) This Quarter
www.americanbankingnews.com - March 17 at 10:06 AM |
| Short Interest in Keryx Biopharmaceuticals (KERX) Drops By 8.4%
www.americanbankingnews.com - March 12 at 1:24 AM |
| Abrams Capital Management L.P. Has $45.19 Million Position in Keryx Biopharmaceuticals (KERX)
www.americanbankingnews.com - March 6 at 4:13 AM |
| Options Traders Expect Huge Moves in Keryx (KERX) Stock
finance.yahoo.com - March 5 at 10:03 AM |
| Reviewing Sierra Oncology (SRRA) and Keryx Biopharmaceuticals (KERX)
www.americanbankingnews.com - March 4 at 11:06 PM |
| Analysts Expect Keryx Biopharmaceuticals (KERX) to Post -$0.19 EPS
www.americanbankingnews.com - February 28 at 9:22 AM |
| Keryx Biopharmaceuticals (KERX) & Seres Therapeutics (MCRB) Head-To-Head Review
www.americanbankingnews.com - February 26 at 3:06 AM |
| Keryx Biopharmaceuticals (KERX) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - February 25 at 6:35 PM |
| Keryx Biopharmaceuticals (KERX) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 24 at 4:30 PM |
| Keryx Biopharmaceuticals Inc (KERX) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 22 at 9:00 AM |
| Keryx Biopharmaceuticals (KERX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 21 at 7:30 PM |
| Keryx Biopharmaceuticals (KERX) CFO Scott A. Holmes Sells 5,651 Shares
www.americanbankingnews.com - February 16 at 10:20 PM |
| Insider Selling: Keryx Biopharmaceuticals (KERX) General Counsel Sells 5,652 Shares of Stock
www.americanbankingnews.com - February 16 at 10:20 PM |
| Keryx Biopharmaceuticals (KERX) Insider Greg Madison Sells 15,318 Shares
www.americanbankingnews.com - February 16 at 10:20 PM |
| Is the Options Market Predicting a Spike in Keryx (KERX) Stock?
finance.yahoo.com - February 13 at 3:25 PM |
 | Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down - Nasdaq
www.nasdaq.com - February 9 at 6:46 AM |
| Earnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% Sensitive
www.nasdaq.com - February 8 at 3:25 PM |
| Earnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% Sensitive
www.nasdaq.com - February 8 at 3:25 PM |
| Keryx (KERX) Posts Wider Q4 Loss, Sales Beat, Shares Down
finance.yahoo.com - February 8 at 3:25 PM |
| Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 8 at 3:25 PM |
| Earnings Reaction History: Keryx Biopharmaceuticals Inc, 22.2% Follow-Through Indicator, 6.4% Sensitive - Nasdaq
www.nasdaq.com - February 8 at 6:36 AM |
 | Keryx Biopharmaceuticals' (KERX) CEO Gregory Madison on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 8 at 6:36 AM |
| Keryx Biopharmaceuticals (KERX) Posts Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - February 7 at 11:12 AM |
 | Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?
www.zacks.com - February 7 at 6:43 AM |
| Keryx (KERX) Warming Up to Q4 Earnings: What's in Store? - Nasdaq
www.nasdaq.com - February 6 at 6:33 AM |
| Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?
finance.yahoo.com - February 5 at 3:24 PM |
Keryx Biopharmaceuticals (NASDAQ:KERX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Keryx Biopharmaceuticals (NASDAQ:KERX) Income Statement, Balance Sheet and Cash Flow Statement
Keryx Biopharmaceuticals (NASDAQ KERX) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
